SINGAPORE APPROVES WHITE PAPER ON HEALTH POLICY

6 December 1993

The Singapore parliament approved a White Paper last month setting out the government's basic health policy and its strategy to control rising health cost. The government has accepted the Paper's recommendations.

The White Paper, prepared by a ministerial committee of Prime Minister Goh Chok Tong's government, said the state will guarantee Singaporeans a good and affordable basic health care package covering most illnesses. Excluded from the package are items like cosmetic surgery, surgery for sex change, in vitro fertilization and "aggressive treatment for incurable diseases."

Singapore opposes state welfarism, and does not encourage government subsidies, doles or free medical treatment for Singaporeans having jobs and/or savings under the Central Provident Fund, a government compulsory old-age savings scheme. Both employers and workers must contribute to the funds a fixed percentage of an employees monthly pay. The government will, as far as possible, rely on competition and market forces to improve the efficiency of the health care system. But where the market fails to keep health care costs down, it will intervene directly. Even destitute persons who cannot afford to pay will be deprived of basic health care. The White Paper said that although Singapore's health care costs are lower than many countries, they are expected to rise as the population ages and the economy matures.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight